Free drugs in clinical trials and their potential cost saving impact on the national health service: A retrospective cost analysis in italy

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 236-240

  Grossi, Francesco ^a   Genova, Carlo ^a   Gaitan, Nidia Diaz ^a   Dal Bello, Maria Giovanna ^a   Rijavec, Erika ^a   Barletta, Giulia ^a   Sini, Claudio ^a   Donato, Caterina ^a   Beltramini, Sabrina ^a   Pronzato, Paolo ^a   Porcile, Gianfranco ^b   Boccardo, Francesco ^a,c   Walzer, Stefan ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b Agenzia Sanitaria Regionale della Liguria (ARS)   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d MArS Market Access and Pricing Strategy GmbH   (Germany)

Author keywords

Clinical trials; Cost savings; Drugs expenditure; Mesothelioma; NSCLC; SCLC

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; VANDETANIB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG INDUSTRY; EXPERIMENTAL THERAPY; HEALTH CARE COST; HEALTH SERVICE; HUMAN; ITALY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MULTIMODALITY CANCER THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

CLINICAL TRIALS; COST SAVINGS; DRUGS EXPENDITURE; MESOTHELIOMA; NSCLC; SCLC;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COST SAVINGS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; ITALY; NATIONAL HEALTH PROGRAMS; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84879882577     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.03.021     Document Type: Article

References (21)

1. Meropol N.J., Schrag D., Smith T.J., Mulvey T.M., Langdon R.M., Blum D., et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009, 27(August (23)):3868-3874.
2. Italian Medicines Agency. Report on the use of medications in Italy for the year 2011. http://www.agenziafarmaco.gov.it/sites/default/files/1_-_rapporto_osmed_2011.pdf.
3. Elting L.S., Shih Y.C. The economic burden of supportive care of cancer patients. Support Care Cancer 2004, 12(April (4)):219-226.
4. Jönsson B., Wilking N. The burden and cost of cancer. Ann Oncol 2007, 18(Suppl. 3):iii9-iii22.
5. American Cancer Society Cancer Facts & Figures 2012 2012, American Cancer Society, Atlanta, GA.
6. Mariotto A.B., Yabroff K.R., Shao Y., Feuer E.J., Brown M.L. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103(January (2)):117-128.
7. Tufts Center for the Study of Drug Development. Outlook Report 2011. http://csdd.tufts.edu/reports/outlook_reports.
8. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 2011, 10(May (5)):328-329.
9. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011, 10(February (2)):87.
10. Redefining cancer drug development: the need for a new roadmap from discovery to drug. Interview with William Hait, Oncologist, Society for Translational Oncology, European Perspectives. http://sto-online.org/content/redefining-cancer-drug-development.
11. NGR014: randomized phase II study of NGR-hTNF in combination with standard chemotherapy versus standard chemotherapy alone in previously untreated patients with advanced Non-Small Cell Lung Cancer (NSCLC). http://clinicaltrials.gov/ct2/show/NCT00994097.
12. Phase II randomised, double-blind, two-arm, parallel study of Vandetanib (ZACTIMA, ZD6474) plus Gemcitabine (Gemzar) or Gemcitabine plus Placebo as first line treatment of advanced (stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly patients. http://clinicaltrials.gov/ct2/show/NCT00753714.
13. An open-label, multicentre, randomized phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly Non-squamous Cell Stage IIIB wet/IV Non-small Cell Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT00871403.
14. A Phase 3, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed + cisplatin for advanced Non-squamous Non-Small Cell Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT00789373.
15. A Phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of AZD6244 (Hyd-Sulfate) in combination with docetaxel, compared with docetaxel alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV). http://clinicaltrials.gov/ct2/show/NCT00890825.
16. A randomized phase 2 study of LY2181308 in combination with docetaxel versus docetaxel in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who were previously treated with First Line Chemotherapy. http://clinicaltrials.gov/ct2/show/NCT01107444.
17. A treatment protocol for patients continuing from a prior SU011248 protocol. http://clinicaltrials.gov/ct2/show/NCT00443534.
18. A multinational, randomized, double-blind study comparing aflibercept versus placebo in patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic Non-Small-Cell Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT00532155.
19. A phase II single-arm trial of BIBW 2992 in EGFR FISH positive Non-small Cell Lung Cancer Patients. http://clinicaltrials.gov/ct2/show/NCT00796549.
20. NGR015: randomized double-blind phase III study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously treated patients with advanced Malignant Pleural Mesothelioma (MPM). http://clinicaltrials.gov/ct2/show/NCT01098266.
21. NGR007: a phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic small cell lung carcinoma (SCLC) previously treated with at least one therapeutic regimen. http://clinicaltrials.gov/ct2/show/NCT00483509.